Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatmentElizabeth F. Krakow, Jean‐Sébastien Delisle, Silvy Lachance et al.|Blood Reviews|2014Cited by 18
Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic CancersElizabeth F. Krakow, Anthony D. Sung, Hui‐Sheng Ai et al.|Current Drug Targets|2015Cited by 16